Lung Small Cell Carcinoma — Trials

Lung Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 381
Recruiting: 202
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (157)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07535359	Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer	available	—	—	Daiichi SankyoINDUSTRY	1	Sep 2, 2026	clinicaltrials
NCT07310277	Expanded Access to ABBV-706	available	—	—	AbbVieINDUSTRY	0	Jan 29, 2026	clinicaltrials
NCT01317953